|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mountain CF: Revisions in the
International System for Staging Lung Cancer. Chest. 111:1710–1717.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nesbitt JC, Putnam JB Jr, Walsh GL, Roth
JA and Mountain CF: Survival in early-stage non-small cell lung
cancer. Ann Thorac Surg. 60:466–472. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fischer OM, Hart S, Gschwind A, Prenzel N
and Ullrich A: Oxidative and osmotic stress signaling in tumor
cells is mediated by ADAM proteases and heparin-binding epidermal
growth factor. Mol Cell Biol. 24:5172–5183. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirao T, Nanba D, Tanaka M, Ishiguro H,
Kinugasa Y, Doki Y, Yano M, Matsuura N, Monden M and Higashiyama S:
Overexpression of ADAM9 enhances growth factor-mediated recycling
of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell
Res. 312:331–339. 2006.PubMed/NCBI
|
|
8
|
Mahimkar RM, Visaya O, Pollock AS and
Lovett DH: The disintegrin domain of ADAM9: a ligand for multiple
beta1 renal integrins. Biochem J. 385:461–468. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O’Shea C, McKie N, Buggy Y, Duggan C, Hill
AD, McDermott E, O’Higgins N and Duffy MJ: Expression of ADAM-9
mRNA and protein in human breast cancer. Int J Cancer. 105:754–761.
2003.
|
|
10
|
Tannapfel A, Anhalt K, Häusermann P,
Sommerer F, Benicke M, Uhlmann D, Witzigmann H, Hauss J and
Wittekind C: Identification of novel proteins associated with
hepatocellular carcinomas using protein microarrays. J Pathol.
201:238–249. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carl-McGrath S, Lendeckel U, Ebert M,
Roessner A and Röcken C: The disintegrin-metalloproteinases ADAM9,
ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol.
26:17–24. 2005.PubMed/NCBI
|
|
12
|
Grützmann R, Lüttges J, Sipos B, Ammerpohl
O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R,
Kalthoff H, Schackert HK, Saeger HD, et al: ADAM9 expression in
pancreatic cancer is associated with tumour type and is a
prognostic factor in ductal adenocarcinoma. Br J Cancer.
90:1053–1058. 2004.
|
|
13
|
Fritzsche FR, Jung M, Tölle A, Wild P,
Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C,
Calvano D, Grützmann R, et al: ADAM9 expression is a significant
and independent prognostic marker of PSA relapse in prostate
cancer. Eur Urol. 54:1097–1106. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fritzsche FR, Wassermann K, Jung M, Tölle
A, Kristiansen I, Lein M, Johannsen M, Dietel M, Jung K and
Kristiansen G: ADAM9 is highly expressed in renal cell cancer and
is associated with tumour progression. BMC Cancer. 8:1792008.
View Article : Google Scholar
|
|
15
|
Zubel A, Flechtenmacher C, Edler L and
Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell
carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qi J and Zhang J: Abnormal expression of
ADAM9 in non-small cell lung cancers. Zhongguo Yike Daxue Xuebao.
39:670–671. 2010.(In Chinese).
|
|
17
|
Zhang J, Qi J, Chen N, Guo Y, Fu W, Zhou B
and He A: Highly expressed ADAM9 in completed resected stage I
non-small cell lung cancer cases predicts a shortened survival. J
Thorac Oncol. 6:s1068–s1069. 2011.
|
|
18
|
Shintani Y, Higashiyama S, Ohta M,
Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H and Matsuura N:
Overexpression of ADAM9 in non-small cell lung cancer correlates
with brain metastasis. Cancer Res. 64:4190–4196. 2004. View Article : Google Scholar
|
|
19
|
Zhang J, Ren H, Yuan P, Lang W, Zhang L
and Mao L: Down-regulation of hepatoma-derived growth factor
inhibits anchorage-independent growth and invasion of non-small
cell lung cancer cells. Cancer Res. 66:18–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J and Mao L: SiRNA targeting
hepatoma-derived growth factor (HDGF) inhibits growth of non-small
cell lung cancer in xenograft models. Tumor Biology 35: Emerging
Molecules, Mechanisms, and Models. Proc Amer Assoc Cancer Res.
47:abstract #5135. 2006.
|
|
21
|
Zhang J, Qi J, Guo Y, Guo Y, Fu W, Zhou B,
Wu G, Han L and He A: Aberrant expression of HDGF and its
prognostic values in surgically resected non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 211–218. 2011.(In Chinese).
|
|
22
|
Besse B and Le Chevalier T: Adjuvant
chemotherapy for non-small-cell lung cancer: a fading effect? J
Clin Oncol. 26:5014–5017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Douillard JY and Gauducheau CR: Adjuvant
chemotherapy for non-small-cell lung cancer: it does not always
fade with time. J Clin Oncol. 28:3–5. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu CQ, Ding K, Strumpf F, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N,
Pintilie M, Der S, et al: Prognostic and predictive gene signature
for adjuvant chemotherapy in resected non-small-cell lung cancer. J
Clin Oncol. 28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie Y and Minna JD: Non-small-cell lung
cancer mRNA expression signature predicting response to adjuvant
chemotherapy. J Clin Oncol. 28:4404–4407. 2010. View Article : Google Scholar : PubMed/NCBI
|
